FR24C1010I1 - DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH - Google Patents

DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH

Info

Publication number
FR24C1010I1
FR24C1010I1 FR24C1010C FR24C1010C FR24C1010I1 FR 24C1010 I1 FR24C1010 I1 FR 24C1010I1 FR 24C1010 C FR24C1010 C FR 24C1010C FR 24C1010 C FR24C1010 C FR 24C1010C FR 24C1010 I1 FR24C1010 I1 FR 24C1010I1
Authority
FR
France
Prior art keywords
diaminopyrimidine
cough
treatment
receptor modulators
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1010C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afferent Pharmaceuticals Inc
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of FR24C1010I1 publication Critical patent/FR24C1010I1/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR24C1010C 2015-09-29 2024-03-12 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH Active FR24C1010I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234584P 2015-09-29 2015-09-29
US201662336381P 2016-05-13 2016-05-13
PCT/US2016/053223 WO2017058645A1 (en) 2015-09-29 2016-09-23 Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough

Publications (1)

Publication Number Publication Date
FR24C1010I1 true FR24C1010I1 (en) 2024-05-24

Family

ID=58424436

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1010C Active FR24C1010I1 (en) 2015-09-29 2024-03-12 DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH

Country Status (20)

Country Link
US (2) US11260056B2 (en)
EP (2) EP4215182A1 (en)
JP (1) JP6877441B2 (en)
KR (1) KR20180054843A (en)
AU (1) AU2016330466B2 (en)
CA (1) CA2998742C (en)
DK (1) DK3355889T3 (en)
ES (1) ES2942711T3 (en)
FI (2) FI3355889T3 (en)
FR (1) FR24C1010I1 (en)
HR (1) HRP20230445T1 (en)
HU (2) HUE061764T2 (en)
LT (1) LT3355889T (en)
MX (1) MX2018003893A (en)
NL (1) NL301260I2 (en)
PL (1) PL3355889T3 (en)
PT (1) PT3355889T (en)
RS (1) RS64155B1 (en)
SI (1) SI3355889T1 (en)
WO (1) WO2017058645A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017378785B2 (en) * 2016-12-20 2021-07-29 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
JOP20200286A1 (en) * 2018-05-15 2020-11-09 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
ES2963702T3 (en) 2018-10-05 2024-04-01 Shionogi & Co Medicine to treat chronic cough
US20220211703A1 (en) * 2019-04-30 2022-07-07 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
AU2020285336A1 (en) 2019-05-31 2022-01-06 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as P2X3 inhibitors
EP3976609A1 (en) 2019-05-31 2022-04-06 Chiesi Farmaceutici S.p.A. Pyridopyrimidines derivatives as p2x3 inhibitors
US20220396561A1 (en) 2019-09-19 2022-12-15 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
CN111635368B (en) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 Preparation method of amine compound
JP2023550840A (en) 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Aminoquinazoline derivatives as P2X3 inhibitors
AU2021386405A1 (en) 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. Phthalazine derivatives as p2x3 inhibitors
AU2021386684A1 (en) 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. (aza)quinoline 4-amines derivatives as p2x3 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100822530B1 (en) 2004-03-05 2008-04-16 에프. 호프만-라 로슈 아게 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
AU2005266887B2 (en) 2004-07-22 2011-08-18 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
DK1924264T5 (en) * 2005-09-01 2014-03-24 Hoffmann La Roche Diaminopyrimidines as P2X3- and P2X2 / 3 modulators
ES2612890T3 (en) 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopyrimidines as modulators of P2X3 and P2X2 / 3
ES2374750T3 (en) 2005-09-01 2012-02-21 F. Hoffmann-La Roche Ag SYNTHESIS PROCESS OF ARYLOXIDIAMINOPIRIMIDINS.
EP1924566B1 (en) 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2008040652A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
MY195728A (en) * 2013-08-23 2023-02-07 Afferent Pharmaceuticals Inc Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough

Also Published As

Publication number Publication date
US11260056B2 (en) 2022-03-01
FI3355889T3 (en) 2023-05-15
SI3355889T1 (en) 2023-07-31
HUE061764T2 (en) 2023-08-28
HUS2400004I1 (en) 2024-04-28
ES2942711T3 (en) 2023-06-06
FIC20240006I1 (en) 2024-03-13
US20180280388A1 (en) 2018-10-04
EP3355889A4 (en) 2019-05-22
US20220143015A1 (en) 2022-05-12
AU2016330466B2 (en) 2021-01-28
CA2998742C (en) 2023-08-29
AU2016330466A1 (en) 2018-03-29
WO2017058645A1 (en) 2017-04-06
HRP20230445T1 (en) 2023-07-21
MX2018003893A (en) 2018-06-22
EP4215182A1 (en) 2023-07-26
KR20180054843A (en) 2018-05-24
JP2018529776A (en) 2018-10-11
NL301260I2 (en) 2024-03-25
PT3355889T (en) 2023-04-26
RS64155B1 (en) 2023-05-31
LT3355889T (en) 2023-05-10
PL3355889T3 (en) 2023-05-22
JP6877441B2 (en) 2021-05-26
CA2998742A1 (en) 2017-04-06
EP3355889A1 (en) 2018-08-08
DK3355889T3 (en) 2023-05-15
EP3355889B1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
FR24C1010I1 (en) DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH
DK3676316T3 (en) LIQUID COMPOSITION INCLUDING BIOLOGICAL UNITS AND USES THEREOF
HK1222126A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough p2x3 p2x2/3
DK3889145T3 (en) 8-cyano-5-piperidino-quinolines as TLR7/8 antagonists and uses thereof for the treatment of immune diseases
MA42819A (en) METHODS FOR THE TREATMENT OF ARENAVIRIDAE AND CORONAVIRIDAE VIRAL INFECTIONS
MA47688A (en) USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY
ITUA20164498A1 (en) METHOD AND APPARATUS FOR THE USE OF DRONES IN FIRE APPLICATIONS
DK3481846T3 (en) 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS
FR3032353B1 (en) PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN
IL291029A (en) Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
ES2972501T3 (en) Devices and methods for exercise or analysis of the neck region
DK3442513T3 (en) USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS
IL265648A (en) P2x3 and/or p2x2/3 compounds and methods
MA50233A (en) MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
MA44762A (en) SEMAGLUTIDE USED IN THE TREATMENT OF CARDIOVASCULAR DISEASES
DE112017006004A5 (en) METHOD AND DEVICE FOR THE CARE OF FLOOR SURFACES AND UNKRAUTED DESCALING DEVICE
FR3036598B1 (en) APPLICATION AND MASSAGE DEVICE
DK3365329T3 (en) NURR1: RXR ACTIVATING COMPOUNDS FOR CONTEMPORARY TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S SICKNESS
MA49524A (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION
MA41120A (en) COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
MA49618A (en) MPO INHIBITORS FOR USE IN MEDICINE
IT201600130012A1 (en) Composition for use in the treatment of disorders of the urogenital system
MA52691A (en) STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES
MA44660A (en) (+) - AZASETRON INTENDED FOR USE IN THE TREATMENT OF EAR DISORDERS
CY1119674T1 (en) Alzheimer's Disease Treatment and Prevention (AD)